Amgen Announces FDA Approval of BioVex Drug Imlygic

Amgen bought BioVex and its Phase III drug Imlygic in March 2011. The upfront payment was $425m with additional payments of up to $575m based on achievement of regulatory and sales milestones.

The US FDA approved Imlygic for sale on 27 October 2015.

In addition, the European regulator (CHMP) recommended on 23 October 2015 that Imlygic be approved by the European Commission.

BioVex Limited

BioVex Limited
Oncology drug development

Website
www.amgen.com